ScholarMate
English简体中文繁體中文
Customer service: 400-1616-289
Sign inSign up
Journal article

Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse

Lin, Chuangzhen; Yu, Bingqing; Liu, Xuelian; Chen, Lixin; Zhang, Zhaohui; Ye, Weixiang; Zhong, Hui; Bai, Wenke; Yang, Yuping; Nie, Biao*南方医科大学
Biomedicine and Pharmacotherapy2022-6DOI: 10.1016/j.biopha.2022.112984
2Cited by19Reads
CiteSave
Share

Abstract

Objective: Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, is believed to alleviate nonalcoholic fatty liver disease (NAFLD) by decreasing hepatic lipogenesis in an FXR-dependent manner. Here, we revealed a novel mechanism by which OCA improves NAFLD by affecting hepatic long-chain fatty acids (LCFAs) uptake. Methods: Stably transfected HEK-293 cells expressing fatty acid transport protein 5 (FATP5) were established to examine fatty acid uptake; FXR-/-, human (h) FATP5, and FXR-/-/hFATP5 mouse models were incorporated to explore the effects of OCA on FATP5 ex vivo and in vivo. Results: OCA inhibited hFATP5 (IC50 =0.07 mu M) more than murine (m) FATP5 (IC50 =1.04 mu M) as measured by LCFAs uptake in FATP5 expressing HEK-293. OCA also inhibited LCFA uptake in primary hepatocytes from hFATP5 mice, FXR-/-/hFATP5 mice more than that from FXR(-/-)mice, ex vivo. Moreover, OCA inhibited LCFAs uptake by livers in hFATP5 mice and FXR-/-/hFATP5 mice, but not in FXR-/- mice, in vivo. Long-term administration of 0.04% OCA markedly reduced hepatic triglyceride (TG) accumulation in hFATP5 mice and FXR-/-/ hFATP5 mice by 63% and 53%, respectively, but not in FXR-/- mice. Conclusions: OCA ameliorated high-fat diet-induced NAFLD independent of FXR by inhibiting hepatic hFATP5mediated LCFAs uptake. This suggests that the therapeutic effects of OCA on NAFLD in vivo are mediated by a novel, hFATP5 dependent mechanism.

Disciplines and keywords

Keywords
Nonalcoholic fatty liver diseaseObeticholic acidFarnesoid X receptorFatty acid transport protein 5Long-chain fatty acids
Related
Loading…

Could not load papers. Please retry.

Retry

Publication info

Publication status
Published
Journal
Biomedicine and Pharmacotherapy
Publication date
2022-06
Volume / issue
Vol. 150
Pages
112984
DOI
10.1016/j.biopha.2022.112984
Language
MULTI-LANGUAGE
Output indexing
SCIE
Funding acknowledgment
Scientific Research Foundation for Returned Scholars of the Ministry of Education of China, China; National Natural Science Foundation of China, China [81471080]

Authors

  • L

    Lin, Chuangzhen (First author)

  • Y

    Yu, Bingqing

View all 10 authorsShow fewer authors
  • L

    Liu, Xuelian

  • C

    Chen, Lixin

  • Z

    Zhang, Zhaohui

  • Y

    Ye, Weixiang

  • Z

    Zhong, Hui

    southern med univ

  • B

    Bai, Wenke

  • Y

    Yang, Yuping

  • N

    Nie, Biao (Corresponding)

Sign in for more features

  • Save this paper in My collections
  • Claim your outputs and generate promotion materials
  • Follow authors for new outputs
  • Join groups and collaborate
Sign up / Sign in

Products

  • ScholarMate
  • InnoCity
  • IRISaaS

Support

  • Help Center
  • Privacy Policy
  • Terms of Service

Contact

Online support: []
Customer service: 400-1616-289
Email: support@scholarmate.com

Follow or download ScholarMate

WeChat QR code
WeChat official account
App download QR code
Download the app
OutputsResearchersResearch institutionsResearch newsIRISaaS

©2026 深圳市科研之友网络服务有限公司

Public security registration badge粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417